Aardvark Therapeutics (AARD) Interest Expenses (2024 - 2025)

Aardvark Therapeutics (AARD) reported Interest Expenses of $16000.0 for Q2 2025, up 1500.0% sequentially from $1000.0 in Q1 2025.

Aardvark Therapeutics (AARD) Interest Expenses (2024 - 2025) Analysis & Trends

Aardvark Therapeutics (AARD) has 2 years of Interest Expenses data on file, last reported at $16000.0 in Q2 2025.

For the quarter ending Q2 2025, Interest Expenses changed N/A year-over-year to $16000.0; the trailing twelve-month figure through Jun 2025 stood at $16000.0 (changed N/A YoY), and the FY2025 full-year result was $12.4 million, down 32.96% from the prior year.
Interest Expenses improved to $16000.0 in Q2 2025, from $1000.0 in the prior quarter.
In the past five years, Interest Expenses ranged from a high of $3.2 million in Q4 2024 to a low of $1000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-42,141.15
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	32.89 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	16.81 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	420.30 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	28.30 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	1.17 Bn
10	Aardvark Therapeutics	139.40 Mn	19.44 Mn	-	-

Download Data